Assessing Risk and Value in Pharmaceutical and Biotech Investment

Wednesday, March 6, 1:00–2:00 PM (ET)

This discussion focused on tools that may be useful in analyzing the likelihood of clinical and regulatory success and the value of health care and life sciences treatments in development. Panelists offered academic and industry perspectives on economic issues in this area, including clinical success rates, deal valuation, and methodological considerations in calculating the value of emerging biotechnology.


Amitabh Chandra

Henry and Allison McCance Professor of Business Administration, Harvard Business School; Ethel Zimmerman Wiener Professor of Public Policy and Director of Health Policy Research, Harvard Kennedy School

Michael Scott Kinch

Executive Dean of Science and Vice President, Innovation, Long Island University


Jee-Yeon Lehmann

Managing Principal, Analysis Group

Sumon Mazumdar

Vice President, Analysis Group

Webinar Recording